INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

Market Wire, November, 2007

For further information, please contact:

Dan Suesskind,          Teva Pharmaceutical Industries Ltd.  972-2-941-1717
Chief Financial Officer

George Barrett,
Corp. E. V.P. - Global  Teva Pharmaceutical Industries Ltd.  (215) 591-3030
 pharmaceutical Markets
Chief Executive Officer Teva North America

Liraz Kalif /           Teva Pharmaceutical Industries Ltd.  972-3-926-7281
Kevin Mannix,           Teva North America                   (215) 591-8912
Investor Relations

Sven Andréasson         Active Biotech                       46 46 19 20 49
President & CEO


Tomas Leanderson        Active Biotech                       46 46 19 20 95
Chief Scientific Officer

Cecilia Hofvander       Active Biotech                       46 46 19 11 22
Manager Corporate Communication

INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY -- http://hugin.info/1002/R/1166589/228490.pdf

Copyright © Hugin ASA 2007. All rights reserved.